[{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fostemsavir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fostemsavir","moa":"HIV-1 attachment","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Extended Release Intramuscular Suspension","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Extended Release Intramuscular Suspension","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Extended Release Intramuscular Suspension","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Extended Release Intramuscular Suspension","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"tablet","sponsorNew":"ViiV Healthcare \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Janssen Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Janssen Pharmaceuticals"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Dispersible tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Extended-release Injectable Suspension","sponsorNew":"ViiV Healthcare \/ Janssen","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Janssen"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable Suspension","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"Integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Janssen Research and Development","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Janssen Research and Development"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Janssen Research and Development","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Janssen Research and Development"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"GSK3640254","moa":"Maturation","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0.22,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.22,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ ViiV Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ ViiV Healthcare"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Dispersible Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Extended-Release Intramuscular Suspension","sponsorNew":"ViiV Healthcare \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Janssen Pharmaceutical"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Bictegravir","moa":"HIV-1 integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Gilead","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Gilead"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ GSK","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ GSK"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ ViiV Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ ViiV Healthcare"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Janssen Pharmaceutical"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Pifzer","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Pifzer"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ ViiV Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ ViiV Healthcare"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Extended-release Intramuscular Suspension","sponsorNew":"ViiV Healthcare \/ ViiV Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ ViiV Healthcare"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dapivirine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Ring","sponsorNew":"ViiV Healthcare \/ ViiV Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ ViiV Healthcare"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Abacavir","moa":"HIV integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Pfizer"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"The Medicines Patent Pool","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Cabotegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"ViiV Healthcare \/ Medicines Patent Pool","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Medicines Patent Pool"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fostemsavir","moa":"gp120","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"ViiV Healthcare \/ GSK","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ GSK"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"GSK3810109A","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Bictegravir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"The Medicines Patent Pool","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Cabotegravir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ The Medicines Patent Pool","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ The Medicines Patent Pool"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"ViiV Healthcare \/ ViiV Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ ViiV Healthcare"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"AIDS Healthcare Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"ViiV Healthcare \/ AIDS Healthcare Foundation","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ AIDS Healthcare Foundation"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ ViiV Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"ViiV Healthcare \/ ViiV Healthcare"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Exavir Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"XVIR-110","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ ViiV Healthcare","highestDevelopmentStatusID":"4","companyTruncated":"ViiV Healthcare \/ ViiV Healthcare"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Fundaci\u00f3n Hu\u00e9sped","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Fundaci\u00f3n Hu\u00e9sped","highestDevelopmentStatusID":"14","companyTruncated":"ViiV Healthcare \/ Fundaci\u00f3n Hu\u00e9sped"}]

Find Clinical Drug Pipeline Developments & Deals by ViiV Healthcare

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Dovato combines the IST inhibitor, dolutegravir with the NRT inhibitor, lamivudine, is the first and only oral, two-drug, single-tablet regimen available for 12 and older living with HIV.

                          Brand Name : Dovato

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 11, 2024

                          Lead Product(s) : Dolutegravir Sodium,Lamivudine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Fundación Huésped

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Through the licensing agreement, the company will focus on advancing XVIR-110, which is currently being evaluated in early-stage clinical trials for the treatment of HIV infections.

                          Brand Name : XVIR-110

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 22, 2024

                          Lead Product(s) : XVIR-110

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Recipient : Exavir Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Apretude (cabotegravir) is an HIV-1 integrase strand transfer inhibitor indicated in at-risk adults and adolescents for PrEP to reduce risk of sexually acquired HIV-1 infection.

                          Brand Name : Apretude

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 13, 2024

                          Lead Product(s) : Cabotegravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The UK MHRA approved two new formulations of cabotegravir (Apretude 30 mg & Apretude 600 mg) for preventing sexually transmitted HIV-1 infection in adults and adolescents.

                          Brand Name : Apretude

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 04, 2024

                          Lead Product(s) : Cabotegravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Dovato (dolutegravir and lamivudine) is the first oral two-drug single-tablet regimen for people aged 12 and older living with HIV.

                          Brand Name : Dovato

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 08, 2024

                          Lead Product(s) : Dolutegravir Sodium,Lamivudine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Cabenuva is a combination of cabotegravir, which inhibits HIV integrase by blocking retroviral DNA integration, and rilpivirine, which inhibits HIV-1 reverse transcriptase.

                          Brand Name : Cabenuva

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 06, 2024

                          Lead Product(s) : Cabotegravir,Rilpivirine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Apretude (cabotegravir) is an integrase strand transfer inhibitor, long acting injection, which is being evaluated for the treatment of HIV-1 infection.

                          Brand Name : Apretude

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 04, 2024

                          Lead Product(s) : Cabotegravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Cabenuva (cabotegravir + rilpivirine) is combination of HIV-1 integrase strand transfer inhibitor & RT inhibitor, being evaluated HIV-1 infection in adults.

                          Brand Name : Cabenuva

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 21, 2024

                          Lead Product(s) : Cabotegravir,Rilpivirine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Dolutegravir is a HIV type 1 integrase inhibitor, which is being evaluated in combination with daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide regimen for HIV-associated tuberculosis.

                          Brand Name : Tivicay

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 14, 2024

                          Lead Product(s) : Dolutegravir Sodium,Rifapentine,Moxifloxacin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Recipient : ACTG

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Apretude (cabotegravir) is an HIV-1 integrase strand transfer inhibitor indicated in at-risk adults and adolescents for PrEP to reduce risk of sexually acquired HIV-1 infection.

                          Brand Name : Apretude

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 10, 2024

                          Lead Product(s) : Cabotegravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank